Last updated: February 14, 2026
What Are the Key Facts of the Litigation?
Purdue Pharma L.P. filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc. on July 16, 2013, in the District of Delaware. The complaint alleges that Teva's generic versions of Purdue’s opioid medications, specifically the controlled-release formulations of oxycodone, infringe on Purdue’s patents related to proprietary technologies for opioid delivery systems.
Case Timeline and Status:
- Filing Date: July 16, 2013
- Patent at Issue: U.S. Patent No. 8,502,651, related to time-release opioid formulations
- Procedural Posture: The case has involved multiple motions, including Teva’s efforts to challenge patent validity via declaratory judgment actions
- Current Status (as of 2023): The case remains active with ongoing pre-trial proceedings, appeals, or settlement negotiations
What Are the Patent and Legal Issues?
Patent Infringement Claims:
Purdue claims Teva infringed its patent by producing and marketing generic oxycodone formulations that incorporate Purdue's protected time-release technology. The patent claims cover specific formulations that achieve extended-release effects, aiming to protect Purdue's market share against earlier generic entry.
Patent Validity Challenges:
Teva has asserted that Purdue’s patent is invalid, arguing that the patent either lacks novelty or is obvious under 35 U.S.C. § 102 and § 103. Teva has filed for declaratory judgment in multiple jurisdictions to challenge the patent's enforceability and validity, citing prior art references and common knowledge in the field.
Procedural Approach:
- Purdue pursued infringement action to enforce patent rights.
- Teva initiated declaratory judgment actions aiming to establish patent invalidity.
- The court has managed several disputes over jurisdiction, claim construction, and motions to dismiss.
What Are the Key Legal Points?
| Issue |
Details |
Significance |
| Patent Scope |
Covers specific extended-release oxycodone formulations |
Defines the boundary of Purdue’s patent rights and potential infringement |
| Obviousness |
Teva claims prior art renders the patent obvious |
Central to patent validity challenge |
| Patent Term |
Likely to have expired or be nearing expiry, given filings in 2013 |
Impacts potential damages and market exclusivity |
| Jurisdiction |
Filed in Delaware, a common venue for patent cases |
Influences procedural strategies and legal outcomes |
What Are the Main Developments and Outcomes?
- Claim Construction: The court has issued rulings on the interpretation of key patent terms, affecting infringement scope.
- Summary Judgment Motions: Both sides have filed motions to dismiss or for summary judgment, with some rulings denying them, allowing the case to proceed.
- Validity Proceedings: Teva’s procedural filings question the validity, with patent office re-examinations or supplemental submissions often intertwined.
- Settlement or Trial? As of 2023, the case remains unresolved, with the potential for settlement, dismissal, or trial depending on subsequent procedural developments.
What Are the Broader Industry Implications?
- Patent Enforcement in Pharmaceuticals: Purdue’s aggressive patent enforcement illustrates protective strategies for proprietary formulations in the highly competitive opioid market.
- Generic Entry and Patent Strategies: The case underscores the importance of patent validity in delaying generic entry, especially against complex formulations.
- Regulatory Environment: Such patent disputes intersect with FDA regulatory pathways, including filing for ANDA approvals and patent linkage.
Key Takeaways
- Purdue is actively defending its extended-release opioid patents against generic challenges by Teva.
- The dispute illustrates tensions around patent validity, especially in high-stakes markets like opioids.
- Patent proceedings in district courts often involve complex claim construction and validity arguments.
- The outcome could influence the timing and scale of generic market entry for Purdue’s or Teva’s opioid products.
- Ongoing legal battles continue to shape patent enforcement strategies and regulatory approaches in pharmaceutical law.
FAQs
1. What patents are involved in Purdue Pharma v. Teva?
Purdue’s U.S. Patent No. 8,502,651, covering specific controlled-release oxycodone formulations, is the primary patent at issue.
2. Why does Teva challenge Purdue’s patent?
Teva claims the patent lacks novelty or is obvious, seeking to produce generic versions without infringing rights and to accelerate market entry.
3. What legal doctrines are central to this case?
Patent infringement, patent validity, and claim construction under 35 U.S.C. §§ 102, 103, and 112.
4. How does this case impact the opioid market?
A ruling favoring Purdue could extend patent protection and delay generic competition; a ruling favoring Teva could threaten Purdue’s market share.
5. Could this case set a precedent for future patent disputes?
Yes, particularly regarding patent validity challenges for complex formulations and the scope of proprietary technology in the pharmaceutical industry.
Sources
- U.S. District Court, District of Delaware, Case No. 1:13-cv-04606.
- Court filings, available via PACER and public court records.
- Patent references and patent office re-examination documents.
- Industry analysis reports on pharmaceutical patent litigation.
- Previous case summaries from legal trackers such as LexisNexis.
[1] U.S. Patent No. 8,502,651.
